Besides corticosteroids, two other drugs are approved for a subset of DMD patients: eteplirsen, an exon-skipping oligonucleotide drug for patients with DMD exon 51 mutations, has received accelerated FDA approval in the USA, and ataluren, a stop codon read-through drug, has conditional approval in Europe for patients with DMD nonsense mutations [16, 19]. This evidence concerns the gene DMD and Duchenne muscular dystrophy.